QIAGEN's GeneReader NGS System Delivers Accuracy and Ease of Use for Clinical Research in Oncology
November 14 2017 - 4:17PM
PR Newswire (US)
HILDEN, Germany and GERMANTOWN, Maryland, November 14, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt
Prime Standard: QIA) today announced new studies highlighting the
outstanding analytical performance and ease of use of the
GeneReader NGS System, the world's first complete Sample to Insight
solution for next-generation sequencing. The studies are being
presented this week at the Association for Molecular Pathology
(AMP) 2017 Annual Meeting in Salt Lake
City, Utah, where QIAGEN also will demonstrate the
GeneReader and other Sample to Insight solutions.
Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-14-GeneReader_AMP?sc_lang=en
Contacts:
QIAGEN
Investor Relations
John Gilardi
+49-2103-29-11711
e-mail: ir@QIAGEN.com
Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: pr@QIAGEN.com
SOURCE Qiagen N.V.
Copyright 2017 PR Newswire
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024